Unmet Need for Safe, Efficient Kidney and Renal Disease Treatments: companiesandmarkets.com

  • Limited competition in kidney and renal disease drug market
  • High unmet need for drugs with strong safety and tolerability profiles
  • Serious side effects noted with use of sevelamer carbonate, lanthanum carbonate, and other phosphate binders

LONDON--(BUSINESS WIRE)-- In 2010 the kidney and renal diseases treatment market was estimated to be worth $50.3billion, and is expected to attain a value of $73 billion by 2017, representing a growth rate of around 5.5% p/a, according to a new report available on companiesandmarkets.com. Growth will result from the introduction of new kidney and renal disease therapies which are undergoing late stage development and regulatory filing.

Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

http://www.companiesandmarkets.com/Market-Report/kidney-and-renal-diseases-therapeutics-market-to-2017-strong-pipeline-and-unmet-need-due-to-poor-safety-profiles-to-create-opportunities-for-growth-617798.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The four major kidney and renal conditions include renal anemia, acute kidney injury, chronic kidney disease and diabetic nephropathy. Although over twelve treatments are currently available for chronic kidney disease (e.g., ACE inhibitors; phosphate binders; ARBs; EPO and iron replacement products); their efficacy levels are not high enough to counter their poor tolerability profiles, and they are no longer in regular use.

Forthcoming kidney and renal therapies offer higher levels of efficacy and strong safety profiles and include metal-free phosphate binders, antioxidant inflammatory modulators, iron replacement treatments and nutritional supplements. Examples of drugs which are deemed particularly promising include AMG 223; AST-120; CellCept; Ferinject; Genz-644470; Hematide; HEPLISAV; Heptar; SBR759 95; Sulodexide; YM533 96; Zuragen and Olmetec, all of which are profiled within the kidney and renal therapeutics market report

The 125 page report, published in July 2011, provides a comprehensive overview of the kidney and renal disease treatment market, enabling the reader to understand the competitive landscape, with a particular focus on the US, Japan, and the top five European countries. Historic and forecast data is provided between 2002-2015.

Profiles of key players included within the kidney disease market research report include Amgen Inc; Merck & Co., Inc; Bristol-Myers Squibb; Hoffmann-La Roche Inc and Shire Inc. It also examines trends in the kidney and renal drug market, as well as mergers/acquisitions, licensing deals, market barriers/drivers and product pipelines.

Report Details:

http://www.companiesandmarkets.com/Market-Report/kidney-and-renal-diseases-therapeutics-market-to-2017-strong-pipeline-and-unmet-need-due-to-poor-safety-profiles-to-create-opportunities-for-growth-617798.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Supplies  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.